Quanterix Corporation announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) establish a robust, complementary two-pronged approach for comprehensive Multiple Sclerosis (MS) disease activity and progression monitoring. The study, led by Professor Jens Kuhle from the University Hospital Basel and University of Basel, demonstrates that these two serum biomarkers provide distinct and critical insights into the MS disease course.
The research found that elevated serum GFAP levels were significantly associated with an increased risk of Progression Independent of Relapse Activity (PIRA)--the slow, progressive deterioration that is difficult to detect with traditional monitoring. This finding is particularly significant, as the paper notes PIRA represents the "biggest unmet therapeutic need in MS." The established role of serum NfL as the gold standard for predicting future relapses and monitoring acute disease activity was also confirmed. The ability to monitor both acute inflammatory activity (NfL) and insidious disease progression (GFAP) offers clinicians a more complete picture of an individual patient's status and risk.
A core component enabling these findings are extensive Simoa-based normative reference databases for both GFAP and NfL. These unprecedented databases, generated from thousands of individuals, are essential for translating test results into meaningful clinical action for individual patients. Because GFAP and NfL values are significantly dependent on age and BMI (for GFAP also sex), the use of absolute cut-off values is unreliable and less informative for individual patients.
With a free, readily available online tool for interpretation of an individual patient's results along with age, sex, and BMI, clinicians can accurately assess a patient's biomarker status and risk of progression. This comprehensive approach--combining highly sensitive assays into a single blood test, large-scale normative data, and an interpretive tool--creates a unique ecosystem towards precision medicine in MS.
